RxDoctor Payments Data

Laura Cosenza

Adult Health · Santa Rosa, CANPI 1376852467

Payments from drug & device makers

$503in general payments, 2019–2025

Across 17 payments — averaging $29.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$207
  • Novo Nordisk$104
  • Lilly USA, LLC$60
  • Tandem Diabetes Care, Inc.$44
  • Medtronic$39
  • Xeris Pharmaceuticals, Inc.$25
  • plus $25 from 1 others

What the payments were for

  • Food & beverage$503100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$503 in reported general payments places this provider in the 55th percentile of 785 adult health providers in California.

See all adult health providers in California

Medicare billing

Part B allowed, 2024
$112,220
Medicare patients
260
Services billed
1,753

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$188,434
JardianceEmpagliflozin42$57,606
MounjaroTirzepatide37$45,886
Tresiba Flextouch U-100Insulin Degludec51$42,893
TrulicityDulaglutide26$33,591
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/714$14,329
Insulin Lispro Kwikpen U-100Insulin Lispro15$9,086
Novolog FlexpenInsulin Aspart27$8,966
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$5,986
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic34$4,715
Nano 2nd Gen Pen NeedlePen Needle, Diabetic24$4,213
HumalogInsulin Lispro12$3,346
Levothyroxine Sodium63$1,269
Metformin Hcl45$562
Metformin Hcl ErMetformin Hcl24$556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$104$188,434104 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$60$82,82375 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 785 adult health providers in California.

Other adult health in Santa Rosa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →